Adma Biologics (ADMA) Non-Current Deffered Revenue (2015 - 2025)

Adma Biologics has reported Non-Current Deffered Revenue for 11 years, with the latest figure at $1.4 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 9.18% year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (down 9.18% YoY), and the FY2025 full-year result was $1.4 million, down 9.18% from the prior year.
• Non-Current Deffered Revenue for Q4 2025 stood at $1.4 million, down from $1.4 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $2.1 million in Q1 2021, with the low at $1.4 million in Q4 2025.
• Historically, Non-Current Deffered Revenue has averaged $1.7 million across 5 years, with a median of $1.7 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue declined 6.42% — and 2025, when it declined 9.18%.
• Adma Biologics' Non-Current Deffered Revenue stood at $2.0 million in 2021, then slipped by 7.23% to $1.8 million in 2022, then decreased by 7.8% to $1.7 million in 2023, then dropped by 8.46% to $1.5 million in 2024, then retreated by 9.18% to $1.4 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.